Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT3PJMV)

• DTT Name: Tyrosine-protein kinase ABL1 (ABL) DTT Info
• Gene Name: ABL1

Molecule-Related Drug & Molecule List

4 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Adenosine triphosphate	DM79F6G	Malnutrition	5B50-5B71	Approved	[1]
Bosutinib	DMTI8YE	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[2]
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[3]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[4]

6 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flumatinib	DM0G5O6	Chronic myelogenous leukaemia	2A20.0	Phase 2	[5]
Saracatinib	DMBLHGP	Hematologic tumour	2B33.Y	Phase 2	[6]
DCC-2036	DMJKFNU	Chronic myeloid leukaemia	2A20	Phase 1/2	[7]
IkT-148009	DMMJ9HY	Parkinson disease	8A00.0	Phase 1	[8]
ISIS-CRP	DMQDUG4	Cardiovascular disease	BA00-BE2Z	Phase 1	[9]
KW-2449	DMFO7RP	Acute myeloid leukaemia	2A60	Phase 1	[10]

17 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
6,6-fused nitrogenous heterocyclic compound 1	DM0VEBI	N. A.	N. A.	Patented	[11]
6,6-fused nitrogenous heterocyclic compound 2	DMB1EAW	N. A.	N. A.	Patented	[11]
6,6-fused nitrogenous heterocyclic compound 3	DMX3VCO	N. A.	N. A.	Patented	[11]
Azaindole derivative 1	DMSMXK3	N. A.	N. A.	Patented	[11]
Azaindole derivative 2	DMXBYHV	N. A.	N. A.	Patented	[11]
Indol-5-ol derivative 1	DM5F8J1	N. A.	N. A.	Patented	[11]
PMID25656651-Compound-28a	DM06LDV	N. A.	N. A.	Patented	[11]
PMID25656651-Compound-28b	DMKB7XV	N. A.	N. A.	Patented	[11]
PMID25656651-Compound-33a	DMCRA2U	N. A.	N. A.	Patented	[11]
PMID25656651-Compound-33b	DMU8ZI3	N. A.	N. A.	Patented	[11]
PMID25656651-Compound-34a	DMWOR8B	N. A.	N. A.	Patented	[11]
PMID25656651-Compound-34b	DMBD706	N. A.	N. A.	Patented	[11]
PMID25656651-Compound-34c	DMG5I41	N. A.	N. A.	Patented	[11]
PMID25656651-Compound-42	DMTUA6E	N. A.	N. A.	Patented	[11]
PMID25656651-Compound-46	DM7XQUT	N. A.	N. A.	Patented	[11]
PMID27774824-Compound-Figure9Example2down	DMXAV42	N. A.	N. A.	Patented	[12]
PMID27774824-Compound-Figure9Example2up	DME3TMS	N. A.	N. A.	Patented	[12]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MC-2001	DMBT2RJ	leukaemia	2A60-2B33	Preclinical	[13]

18 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	DMSKJ1X	Discovery agent	N.A.	Investigative	[14]
AP-24226	DMGTEXD	Discovery agent	N.A.	Investigative	[15]
BAS-00387275	DMZPKGS	Discovery agent	N.A.	Investigative	[16]
BAS-00387328	DM4OSFD	Discovery agent	N.A.	Investigative	[16]
BAS-00387347	DMUF28Q	Discovery agent	N.A.	Investigative	[16]
BAS-00672722	DM6R4X8	Discovery agent	N.A.	Investigative	[16]
BAS-01373578	DMZBIC3	Discovery agent	N.A.	Investigative	[16]
BAS-0338872	DMZK0SC	Discovery agent	N.A.	Investigative	[17]
BAS-0338876	DMBS8N9	Discovery agent	N.A.	Investigative	[17]
BAS-09534324	DMFMBZ9	Discovery agent	N.A.	Investigative	[16]
Bis-(5-hydroxy-1H-indol-2-yl)-methanone	DMTSEXB	Discovery agent	N.A.	Investigative	[18]
JNJ-10198409	DM9GDP5	Discovery agent	N.A.	Investigative	[19]
MYRISTIC ACID	DMYX0BL	Discovery agent	N.A.	Investigative	[20]
PD-0166326	DMD2CG9	Discovery agent	N.A.	Investigative	[21]
PD-0173956	DM8RW92	Discovery agent	N.A.	Investigative	[21]
TG-100435	DMIR3X2	Discovery agent	N.A.	Investigative	[22]
TRISMETHOXYRESVERATROL	DM6USPC	Discovery agent	N.A.	Investigative	[23]
[1,1':2',1'']-terphenyl-4,3'',5''-triol	DMVOY4D	Discovery agent	N.A.	Investigative	[23]

References

• [1] Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15.
• [2] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [5] Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci. 2014 Jan;105(1):117-25.
• [6] Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
• [7] Company report (Deciphera Pharmaceuticals: Tumor-Targeted Programs and Indications)
• [8] The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson's disease. Sci Transl Med. 2023 Jan 18;15(679):eabp9352.
• [9] Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. J Med Chem. 2008 Mar 13;51(5):1252-9.
• [10] KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009 Aug 20;114(8):1607-17.
• [11] Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
• [12] Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
• [13] Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia. 2003 Oct;17(10):1961-6.
• [14] 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
• [15] Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP2453... J Med Chem. 2010 Jun 24;53(12):4701-19.
• [16] A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86.
• [17] Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1207-11.
• [18] Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
• [19] (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73.
• [20] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [21] Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6.
• [22] Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8.
• [23] Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8.